Comprehensive assessment of oncological outcomes in 186 patients with high-risk non-muscle-invasive bladder cancer: A single institution retrospective study.
high-risk non-muscle-invasive bladder cancer
overall survival
progression-free survival
recurrence-free survival
tumor multiplicity
Journal
Molecular and clinical oncology
ISSN: 2049-9450
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
01
06
2019
accepted:
01
06
2020
entrez:
6
8
2020
pubmed:
6
8
2020
medline:
6
8
2020
Statut:
ppublish
Résumé
The aims of the current study were to analyze the oncological outcomes of patients with high-risk non-invasive bladder cancer (NMIBC) and to identify prognostic factors in these patients. The present study included 186 consecutive patients who underwent transurethral resection of the bladder tumor (TURBT) between January 2007 and June 2017 at Hamamatsu University School of Medicine and were subsequently diagnosed with high-risk NMIBC according to the classification of the European Urological Association guidelines. The oncological outcomes, including recurrence-free survival (RFS), progression-free survival (PFS) and overall survival (OS) in the 186 patients were evaluated. Additionally, the effects of several clinicopathologiocal parameters on these outcomes were investigated. After the initial TURBT, the second transurethral resection and intravesical bacillus of Calmette-Guerin (BCG) therapy were performed for 47 (25.3%) and 108 (58.1%) patients, respectively. During the observation period of the current study, disease recurrence, disease progression and overall deaths occurred in 54 (29.0%), 14 (7.5%) and 19 (10.2%) patients, respectively. The 5-year RFS, PFS and OS rates in the 186 patients were 66.6, 90.2 and 87.2%, respectively. Multivariate analyses using the Cox proportional hazards regression model identified the following independent factors for the oncological outcomes: Tumor multiplicity and introduction of BCG therapy for RFS (P=0.018 and P<0.008, respectively), tumor multiplicity and recurrence status for PFS (P=0.043 and P=0.029, respectively), and age and tumor multiplicity for OS (P<0.008 and P=0.041, respectively). Although management following initial TURBT was insufficient, the oncological outcomes in the present series were comparable to those in previous studies targeting high-risk patients with NMIBC. However, attention should be paid to patients with factors independently associated with poor prognostic outcomes, particularly those with multiple tumors.
Identifiants
pubmed: 32754330
doi: 10.3892/mco.2020.2086
pii: MCO-0-0-02086
pmc: PMC7391835
doi:
Types de publication
Journal Article
Langues
eng
Pagination
16Informations de copyright
Copyright © 2020, Spandidos Publications.
Références
Urol Oncol. 2015 Mar;33(3):110.e11-8
pubmed: 25262382
Urology. 2005 Dec;66(6 Suppl 1):4-34
pubmed: 16399414
Eur Urol. 2017 Mar;71(3):447-461
pubmed: 27324428
Eur Urol. 2015 Jan;67(1):74-82
pubmed: 25043942
BJU Int. 2013 Oct;112(6):742-50
pubmed: 23452187
Urol Oncol. 2014 Jan;32(1):42.e13-9
pubmed: 24360660
J Urol. 2013 Aug;190(2):480-6
pubmed: 23376707
Clin Genitourin Cancer. 2013 Jun;11(2):182-8
pubmed: 23276589
Urol Oncol. 2018 Jul;36(7):313-320
pubmed: 29573965
Scand J Urol. 2015 Apr;49(2):127-32
pubmed: 25331368
Urol Oncol. 2015 Jan;33(1):20.e9-20.e17
pubmed: 25443267
BJU Int. 2011 Jul;108(2):187-95
pubmed: 21176079
Int J Urol. 2009 Mar;16(3):279-86
pubmed: 19207609
Clin Genitourin Cancer. 2017 Feb;15(1):e25-e31
pubmed: 27432529
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7
pubmed: 16442208
Scand J Urol Nephrol. 2005;39(3):206-10
pubmed: 16127800
Eur Urol. 2015 Aug;68(2):238-53
pubmed: 25709027
World J Urol. 2011 Aug;29(4):409-14
pubmed: 21190023
J Urol. 2003 Aug;170(2 Pt 1):433-7
pubmed: 12853793
Med Hypotheses. 2016 Jul;92:57-8
pubmed: 27241256
Urol Oncol. 2016 Nov;34(11):485.e7-485.e14
pubmed: 27637323
Urol Oncol. 2011 Sep-Oct;29(5):495-501
pubmed: 19914103
J Oncol Pract. 2013 Mar;9(2):92-8
pubmed: 23814517
Br J Cancer. 2013 Sep 17;109(6):1460-6
pubmed: 23982601
Urol Int. 2014;92(2):131-5
pubmed: 23988813
BJU Int. 2015 Nov;116(5):721-6
pubmed: 25715815
J Clin Oncol. 2015 Feb 20;33(6):643-50
pubmed: 25559810
J Urol. 2009 Nov;182(5):2195-203
pubmed: 19758621
Front Oncol. 2019 Jan 17;8:642
pubmed: 30705874
Hematol Oncol Clin North Am. 2015 Apr;29(2):227-36, viii
pubmed: 25836931
Eur Urol. 2011 Sep;60(3):493-500
pubmed: 21664041